Marché européen des tests de sang occulte dans les selles – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des tests de sang occulte dans les selles en Europe

L'un des principaux facteurs à l'origine de la croissance du marché des tests de recherche de sang occulte dans les selles est l'augmentation du nombre de cas de cancer colorectal en Europe. Les recherches cliniques continues menées par plusieurs entreprises pour améliorer le diagnostic conduisent à l'expansion du marché. Le marché est également influencé par le développement des tests de laboratoire directs aux consommateurs et par la disponibilité facile des appareils de test immunologique de recherche de sang occulte dans les selles dans les magasins en ligne.

Le marché européen des tests de sang occulte dans les selles devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 5,1 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 686,40 millions USD d'ici 2030.

Définition du marché

Le test de recherche de sang occulte dans les selles (FOBT) est un test de dépistage diagnostique effectué pour analyser le sang caché (occulte) dans les échantillons de selles. Le test de recherche de sang occulte dans les selles est également connu sous le nom de sang occulte dans les selles, immuno-essai FOBT, hémoocculte et IFOBT et test de frottis au gaïac. Le test est principalement utilisé pour dépister le cancer du côlon et analyser les causes possibles d'une anémie inexpliquée.

Dynamique du marché des tests de sang occulte dans les selles

Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :

Conducteurs

• Augmentation des cas de cancer colorectal en Europe

Colorectal cancer is a disease of the colon or rectum, which are parts of the digestive system. Unlike most cancers, colorectal cancer is often preventable with screening & can be treated when detected early. Most cases of colorectal cancer occur in people ages 45 & older. The disease is increasingly affecting younger people due to unhygienic lifestyles & smoking habits. Colorectal cancers may develop without symptoms. The common symptoms may include blood in or on the stool, persistent unusual bowel movements like constipation or diarrhea, stomach pain, aches or cramps that last longer and losing weight for no reason.

Most colorectal cancers start as abnormal tissue growth, called a polyp, inside the colon or rectum. Doctors can detect polyps with the help of screening tests & can remove them from developing into colorectal cancer. Even if it spreads into nearby lymph nodes, chemotherapy & surgical treatments are effective ways to treat colorectal cancer. Research is going on to learn more about this disease and provide more hope to people with all stages of colorectal cancer.

• Direct-to-consumer Laboratory Testing

Direct-to-consumer laboratory testing is an effective way for users where they can order their corresponding laboratory tests directly from a lab without any healthcare providers. Nowadays, the healthcare industry is shifting towards direct-to-consumer laboratory testing from physician-based lab testing & hence the demand has increased drastically. Most of the patients are focusing on direct-to-consumer based laboratory tests without going through a lengthy in-clinic process, which is fueling the growth of the fecal occult blood tests market.

For the identification of previously unknown medical disorders, the test results are used. The advancements in the field of direct-to-consumer laboratory testing have become crucial to increase patient engagement for better monitoring & screening of existing health conditions. Hence, it is very important for laboratory professionals to upgrade the devices & instruments used in testing laboratories.

• Easy Availability Of Fecal Occult Immunological Test Devices In Online Stores

A fecal occult blood test (FOBT) generally focuses on a stool sample to check for blood. The presence of blood in stool refers that there is bleeding in the digestive tract. The bleeding can be caused by a variety of conditions like Polyps (abnormal growths on the lining of the colon or rectum), Hemorrhoids (swollen veins in the anus or rectum), Diverticulosis (a condition with small pouches in the inside wall of the colon), Ulcers (sores in the lining of the digestive tract), Colitis (a type of inflammatory bowel disease) and Colorectal cancer.

There are a huge number of fecal occult immunological test devices available in the market, and people can buy the kits & devices from various online sites. Hence, it can be a driving factor for the growth of the fecal occult blood tests market.

Opportunities

• Increase in screening procedures

Most government agencies and scientific societies recommend cervical, breast, and colorectal screening because of the burden of these cancers, the availability of screening tests, and the proven efficacy of screening in reducing mortality, as well as incidence, for cervical and colorectal cancers.

The European Community recommends the implementation of population-based screening programs for colorectal cancers. This recommendation is supported by many observational studies showing that organized programs effectively reduce mortality and control the inappropriate use of screening tests.

• Rising technical advancements

A blood test has always been a technology- and data-dependent field. As data and technology potentially revolutionized diagnostic services and had positioned to partner with patients, families, practitioners, researchers, industry leaders, policymakers, and administrators to ensure that humanistic, high-value, ever-improving precise diagnosis remains the central goal for the future of blood test diagnosis.

The use of fecal occult blood testing has expanded to several indications, even though its primary use is for evaluating an occult source of GI blood loss and for home-based kits in colorectal carcinoma screening. One of the most common clinical uses for the hemoccult is for checking a stool specimen for occult bleeding prior to anticoagulation.

Restraints/Challenges

• Change In Consumer Preference Towards Cost-Effective Alternatives

The fecal occult blood test products bear a high cost and usually cannot be afforded by everyone in general. As technology is getting more advanced day by day & there are a number of test alternatives available in the market. Hence, people prefer cost-effective alternatives for fecal occult blood tests. There are various screening programs that often target people with apparently healthy conditions & the number of people using screening services is usually higher than the true number of patients. The FOBT has advantages over colonoscopy in terms of being less costly and easy to perform.

As most of the fecal occult blood test alternatives are available in the market. Hence, people prefer substitutes with lesser cost & more accurate results. Hence, the change in consumer preference toward cost-effective alternatives may restrain the market growth in the forecast period.

• Low efficiency

The fecal occult blood test is not always accurate and could show a negative test result when cancer is present and have a false-negative result if cancer or polyps do not bleed.

The test could show a positive result when the person has no cancer (false-positive result) or have bleeding from other sources, such as a stomach ulcer, hemorrhoid, or even blood swallowed from the mouth or nose.

Post-COVID-19 Impact on the Fecal Occult Blood Tests Market

The COVID-19 pandemic had a great impact on the fecal occult blood test industries. Trade groups in colorectal cancer and gastrointestinal bleeding diagnostic products sector claim that the Europe supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the fecal occult blood tests market. Sales of test products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care and fecal occult blood test instruments.

Recent Developments

• In November 2022, Eiken Chemical Co, Ltd. had launched the fully automated fecal immunochemical test/ Faecal Calprotectin Analyzer “OC-SENSOR Ceres.” This has helped the company to establish its product Europely
• In January 2022, Boditech Med Inc. announced that it had signed a USD19.2 Million supply agreement with A. Menarini Diagnostics to accelerate its product portfolio. This helps the organization in generating revenue

Europe Fecal Occult Blood Tests Market Scope

The Europe fecal occult blood tests market is segmented into four notable segments based on test type, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Test Type

• Lateral Flow Immuno-FOB Test Kits
• Immuno-FOB Agglutination Test Kits
• Immuno-FOB ELISA Test Kits
• Guaiac FOB Stool Tests
• Flushable Reagent Pad Or Tissue
• Others

On the basis of test type, the Europe fecal occult blood tests market is segmented into lateral flow immuno-FOB test kits, immuno-FOB agglutination test kits, immuno-FOB ELISA test kits, guaiac FOB stool tests, flushable reagent pad or tissue, and others.

Application

• Colorectal Cancer Screening
• Concern For Gastrointestinal Bleeding
• Polyps
• Diverticulosis
• Ulcers
• Haemorrhoids
• Colitis
• Anemia
• Others

On the basis of application, the Europe fecal occult blood tests market is segmented into Colorectal Cancer Screening, Concern for gastrointestinal bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and others.

End User

• Diagnostic Laboratories
• Hospitals
• Specialty Clinics
• Others

Sur la base de l’utilisateur final, le marché européen des tests de sang occulte dans les selles est segmenté en laboratoires de diagnostic, hôpitaux, cliniques spécialisées et autres.

Canal de distribution

• Appel d'offres direct
• Ventes au détail
• Commerce électronique
• Autres

Sur la base du canal de distribution, le marché européen des tests de sang occulte dans les selles est segmenté en appels d'offres directs, ventes au détail, commerce électronique et autres.

Analyse/perspectives régionales du marché des tests de sang occulte dans les selles

Le marché des tests de sang occulte dans les selles est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de test, application, utilisateur final, canal de distribution, comme référencé ci-dessus.

Le marché européen des tests de sang occulte dans les selles comprend les pays suivants : Russie, Espagne, Turquie, Allemagne, Italie, Royaume-Uni, France, Belgique, Suisse, Pays-Bas et reste de l'Europe.

L'Allemagne devrait dominer le marché européen des tests de sang occulte dans les selles en raison d'une tendance croissante vers les diagnostics au point de service. Une augmentation de la demande de produits de test de sang occulte dans les selles et une augmentation des activités de recherche et développement dans l'industrie devraient également stimuler le marché au cours de la période prévue.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des tests de sang occulte dans les selles en Europe

Le paysage concurrentiel du marché des tests de sang occulte dans les selles fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que les entreprises se concentrant sur le marché européen des tests de sang occulte dans les selles.

Français Certains des principaux acteurs opérant sur ce marché sont Biopanda Reagents Ltd., ulti med Products (Deutschland) GmbH, CERTEST BIOTEC., Alfa Scientific Designs, Inc., Biohit Oyj, Hangzhou Clongene Biotech Co., Ltd., Wondfo., PRIMA Lab SA, Boditech Med Inc., Epitope Diagnostics, Inc., Accuquik Test Kits, Aidian, Apacor Limited, Quidel Corporation., Eurolyser Diagnostica GmbH, Siemens Healthcare GmbH et Eiken Chemical Co., Ltd., entre autres.

SKU-69790